Everhart Financial Group Inc. Increases Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Everhart Financial Group Inc. boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 72.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,285 shares of the company's stock after buying an additional 539 shares during the quarter. Everhart Financial Group Inc.'s holdings in IDEXX Laboratories were worth $540,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Marshall Financial Group LLC increased its stake in IDEXX Laboratories by 14.5% during the first quarter. Marshall Financial Group LLC now owns 2,286 shares of the company's stock valued at $960,000 after acquiring an additional 290 shares during the period. Mogy Joel R Investment Counsel Inc. boosted its position in IDEXX Laboratories by 8.1% during the 1st quarter. Mogy Joel R Investment Counsel Inc. now owns 85,724 shares of the company's stock worth $36,000,000 after acquiring an additional 6,400 shares during the last quarter. Fifth Third Bancorp lifted its stake in IDEXX Laboratories by 102.2% in the first quarter. Fifth Third Bancorp now owns 6,075 shares of the company's stock valued at $2,551,000 after acquiring an additional 3,071 shares during the last quarter. Simon Quick Advisors LLC acquired a new stake in IDEXX Laboratories during the first quarter worth approximately $360,000. Finally, CX Institutional bought a new position in IDEXX Laboratories during the 1st quarter worth $215,000. Hedge funds and other institutional investors own 87.84% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on IDXX shares. Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Leerink Partners increased their price objective on IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a report on Wednesday, June 11th. Stifel Nicolaus raised their target price on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a report on Monday, May 19th. Finally, Morgan Stanley increased their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of "Moderate Buy" and a consensus target price of $546.00.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the sale, the director now owns 1,801 shares of the company's stock, valued at $922,724.34. This trade represents a 41.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Price Performance

NASDAQ IDXX traded up $6.07 on Monday, reaching $528.77. The company's stock had a trading volume of 371,831 shares, compared to its average volume of 649,497. The firm's 50 day moving average is $473.11 and its two-hundred day moving average is $444.61. The stock has a market cap of $42.52 billion, a PE ratio of 49.56, a PEG ratio of 3.41 and a beta of 1.55. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $540.79. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The firm had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. During the same quarter in the prior year, the company earned $2.71 EPS. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.